Ashwagandha (Withania somnifera) Reverses β-Amyloid1-42 Induced Toxicity in Human Neuronal Cells: Implications in HIV-Associated Neurocognitive Disorders (HAND)
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized by progressive dysfunction of memory and higher cognitive functions with abnormal accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles throughout cortical and limbic brain regions. At present no curative treatment is available, and research focuses on drugs for slowing disease progression or providing prophylaxis. Withania somnifera (WS) also known as 'ashwagandha' is used widely in Ayurvedic medicine as a nerve tonic and memory enhancer. However, there is a paucity of data on the potential neuroprotective effects of W.somnifera against β-Amyloid (1-42)-induced neuropathogenesis. In the present study, we have tested the neuroprotective effects of methanol:Chloroform (3:1) extract of ashwagandha against β-amyloid induced toxicity and HIV-1Ba-L (clade B) infection using a human neuronal SK-N-MC cell line. Our results showed that β-amyloid induced cytotoxic effects in SK-N-MC cells as shown by decreased cell growth when tested individually. Also, confocal microscopic analysis showed decreased spine density, loss of spines and decreased dendrite diameter, total dendrite and spine area in clade B infected SK-N-MC cells compared to uninfected cells. However, when ashwagandha was added to β-amyloid treated and HIV-1 infected samples, the toxic effects were neutralized. Further, the MTT cell viability assays and the peroxisome proliferator-activated receptor-γ (PPARγ) levels supported these observations indicating the neuroprotective effect of WS root extract against β-amyloid and HIV-1Ba-L (clade B) induced neuro-pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
Protein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454 · cited 1×
“The pathological hallmarks are complex and include neuronal degeneration (cholinergic neurons in particular), abnormal neurofibrillary tangles, toxic β-amyloid (AB) plaques, decline of neurochemicals which are essential for neuronal transmission and neuro-inflammation [4-6].”
BackgroundHydrogen peroxide mediates amyloid β protein toxicity
Behl, C. (1994) · Cell · doi:10.1016/0092-8674(94)90131-7 · Cited by 2,074 · cited 1×
“by free radicals and oxidative stress [28,49-53].”
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975 · cited 3×
“Michaelis et al [26] used 5 and 10 μM concentration on cortical cell cultures whereas Yankner et al [27] used 20 μM on hippocampal neurons.”
BackgroundMethodTwenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Role of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798 · cited 2×
“familial cases are caused primarily by mutations in three genes namely, amyloid precursor protein (APP), presenilin1 (PS1), and presenilin 2 (PS2) [10].”
BackgroundAlzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.014 · Cited by 1,004
The Genetics of Alzheimer Disease: Back to the Future
Bertram, L., Lill, C. M., & Tanzi, R. E. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.013 · Cited by 834
Control of Macrophage Activation and Function by PPARs
Chawla, A. (2010) · Circulation Research · doi:10.1161/circresaha.110.216523 · Cited by 531 · cited 1×
“In general, β-amyloid deposition elicits a vigorous “M1” microglia-mediated inflammatory response contributing to disease progression [71-73].”
BackgroundA Hundred Years of Alzheimer's Disease Research
Hardy, J. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.016 · Cited by 467
Cited by
Pharmacologic overview of Withania somnifera, the Indian Ginseng
Dar, N. J., Hamid, A., & Ahmad, M. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2012-1 · Cited by 370
Ethnomedicinal uses of the local flora in Chenab riverine area, Punjab province Pakistan
Umair, M., Altaf, M., Bussmann, R. W., & Abbasi, A. M. (2019) · Journal of Ethnobiology and Ethnomedicine · doi:10.1186/s13002-019-0285-4 · Cited by 342
Mikulska, P., Malinowska, M., Ignacyk, M., Szustowski, P., Nowak, J., Pesta, K., Szeląg, M., Szklanny, D., Judasz, E., Kaczmarek, G., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041057 · Cited by 324
Paul, S., Chakraborty, S., Anand, U., Dey, S., Nandy, S., Ghorai, M., Saha, S. C., Patil, M. T., Kandimalla, R., Proćków, J., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112175 · Cited by 306
Choudhary, D., Bhattacharyya, S., & Bose, S. (2017) · Journal of Dietary Supplements · doi:10.1080/19390211.2017.1284970 · Cited by 215
Natural Withanolides in the Treatment of Chronic Diseases
White, P. T., Subramanian, C., Motiwala, H. F., & Cohen, M. S. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-41334-1_14 · Cited by 139
Effects of Ashwagandha (Roots of Withania somnifera) on Neurodegenerative Diseases
Kuboyama, T., Tohda, C., & Komatsu, K. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00022 · Cited by 127
Neurodegenerative diseases and Withania somnifera (L.): An update
Dar, N. J., & Ahmad, M. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112769 · Cited by 123
Sun, G. Y., Li, R., Cui, J., Hannink, M., Gu, Z., Fritsche, K. L., Lubahn, D. B., & Simonyi, A. (2016) · NeuroMolecular Medicine · doi:10.1007/s12017-016-8411-0 · Cited by 95
“Recent studies in vitro also provided evidence for Ashwagandha extracts and their bioactive constituents to offer neuroprotective effects and modulate neurite outgrowth (Dar et al. 2015; Kuboyama et al. 2014; Kurapati et al. 2015; Kurapati et al. 2013; Shah et al. 2015).”
BackgroundPotential clinical applications of Ashwagandha (Withania somnifera) in medicine and neuropsychiatry
D’Cruz, M., & Andrade, C. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2121699 · Cited by 40
Metadata
- Authors
- Kurapati, K. R. V., Atluri, V. S. R., Samikkannu, T., & Nair, M. P. N.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-10-16
- Volume
- 8
- Issue
- 10
- Pages
- e77624
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1996636308
- Cited by
- 129
- References
- 26
- FWCI
- 21.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.